The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000915358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
10/07/2026
Date registered
Help: Date registered
24/07/2026
Date last updated
Help: Date last updated
24/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
24/07/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Feasibility of First Pass Cannulation Success Rate in Peripheral Intravenous Cannulation on Adults Using a Novel Ultrasound Device
Scientific title
Feasibility of First Pass Cannulation Success Rate in Peripheral Intravenous Cannulation on Adults Using a Novel Ultrasound Device
Additional trial identifiers [1] 317869 0
Clinical Trial CT-2025-CTN-02593-1 v1
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Peripheral intravenous access 342808 0
Condition category
Condition code
Anaesthesiology 338929 338929 0 0
Other anaesthesiology
Public Health 339017 339017 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study aims to evaluate the usability and clinical effectiveness of the VeinWise device, a portable, ergonomically designed handheld system that displays simplified pathways of veins reconstructed from ultrasound data. The primary objective is to assess the device's performance in facilitating vein visualization during peripheral intravenous cannulation (PIVC), which is one of the most commonly performed medical procedures. The study will not involve direct comparisons with other devices but will focus on assessing the standalone functionality and user experience of the VeinWise prototype in a controlled clinical environment.

The novel ultrasound device that will be used for this study will be the VeinWise ultrasound device, which has not been regulatory approved. This is a portable and handheld prototype that displays simplified pathways of veins reconstructed from continuous wave doppler ultrasound data. The prototype was assembled under ISO13485 Quality Management Systems and safety has been ensured through risk assessment. The device weighs less than 200g, it scans an area of the forearm 20x30mm and displays the scanned area 1:1 on a screen. The device is designed to be held in a clinicians non-cannulating hand, visualising the vessel pathway to enable clinicians to align their catheter in the correct location and angle. An off-the-shelf ultrasound probe cover is placed around the device to maintain sterility. Sterile ultrasound gel is placed under the sensor to ensure signal transmission. The device is then placed on the participants forearm.

Patients will be recruited in this study, as well as voluntary clinical professionals. Each patient will be recruited face to face, and their participation will last ~1 hour. It will occur in a Hospital. Each clinician will be recruited face to face, and their participation will range but will likely involve, 1 training session and ~3 cannulations. Clinicians have access to revisit all training material, plus quick-reference guides before every cannulation. During the procedure, clinicians will assess the patients forearm vessels using the device, if they are confident to cannulate a vessel they will then attempt cannulation with device visualisation assistance. If successful the patient will answer questions about their experience. Following one failed attempt (only one attempt will be permitted), the Vascular Access Specialist will insert the cannula using commercial ultrasound.

To ensure safe and effective use of the device and to answer any technical queries, a product engineer will be present during the procedures. Training involves clinicians reading an instructions for use manual, watching a workflow video, and performing cannulation on a simulation forearm model made of silicone. Adherence or fidelity to the use of the device will not be formerly assessed, however the technical expert will always be present to ensure safe and proper workflow adherence.
Intervention code [1] 334709 0
Treatment: Devices
Description of the comparator or control
No control group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346154 0
First cannulation insertion success rate
Timepoint [1] 346154 0
Intervention at time of insertion.
Secondary outcome [1] 464820 0
Clinician Satisfaction
Timepoint [1] 464820 0
Measured Post-cannulation, immediately after the patient has left
Secondary outcome [2] 464821 0
Escalation Pathway taken to reach successful cannulation. Eg. ultrasound used to placed in brachial vein or patient escalated to central line placement.
Timepoint [2] 464821 0
Measured following a Post-cannulation failure, once the vascular access specialist has successfully placed the cannula
Secondary outcome [3] 465262 0
Suitability of vessel
Timepoint [3] 465262 0
Measured immediately following post-cannulation success using commercial ultrasound

Eligibility
Key inclusion criteria
Patients who require peripheral intravenous access in peripheral vessels in the hospital that is conducting the study.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Medically unstable/unsuitable
2. Allergic to ultrasound gel
3. Unable to provide informed consent (e.g. cognitive impairment)
4. Being pregnant
5. Under 18 years of age
6. Skin conditions in forearm area (e.g. burns, fibrous tissue, eczema, psoriasis etc.)
7. Patient who requires immediate intervention
8. Patients with any form of psychiatric disorder, or any chronic condition that could, in the opinion of the investigator, interfere with the conduct of the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
A formal sample size calculation is not applicable for this study due to the absence of existing data on first-pass cannulation success rates when using the novel VeinWise prototype device. As this is an exploratory study designed to evaluate the usability and clinical effectiveness of a new technology, the primary goal is to gather preliminary data that will inform the design of future, larger-scale studies with higher statistical power.
Descriptive statistics are performed on patient characteristics for all patients. Dichotomous data are presented as percentages. Continuous variables are categorized into logical groups for analysis. Vessel depth is divided into three zones: shallow (1.2cm). Vessel diameter is divided into four groups (0.5cm). Blood velocity is divided into three groups (50mm/s). The Fisher exact test and Kruskal Wallis test are used for comparisons of categorical variables, as appropriate. Backwards variable elimination procedure with single hierarchy is used to identify which variables are significantly (.05 level) and independently associated with VWG first pass success in a logistic regression model. At each step of the procedure, individual parameters are examined using the Wald Chi-Square test. Multicollinear variables are removed from the procedure, such as palpation prior to torniquet application, ensuring correct statistical significance calculations.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 29819 0
Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 46172 0
6150 - Murdoch

Funding & Sponsors
Funding source category [1] 322405 0
Commercial sector/Industry
Name [1] 322405 0
VeinTech Pty Ltd
Country [1] 322405 0
Australia
Funding source category [2] 322408 0
Hospital
Name [2] 322408 0
Fiona Stanley Hospital
Country [2] 322408 0
Australia
Funding source category [3] 322409 0
Government body
Name [3] 322409 0
South Metropolitan Health Service Executive
Country [3] 322409 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
VeinTech Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325334 0
None
Name [1] 325334 0
Address [1] 325334 0
Country [1] 325334 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320904 0
South Metropolitan Health Service Human Research Ethics Committee
Ethics committee address [1] 320904 0
Ethics committee country [1] 320904 0
Australia
Date submitted for ethics approval [1] 320904 0
06/06/2025
Approval date [1] 320904 0
11/06/2025
Ethics approval number [1] 320904 0
RGS0000007247 (initial submission approved by SMHS HREC)
Ethics committee name [2] 320907 0
WA Health Central HREC
Ethics committee address [2] 320907 0
Ethics committee country [2] 320907 0
Australia
Date submitted for ethics approval [2] 320907 0
05/06/2026
Approval date [2] 320907 0
07/07/2026
Ethics approval number [2] 320907 0
RGS0000007247 (HREC changed following initial project approval, latest amendment approved by Central)

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152022 0
Mr Michael D Liddelow
Address 152022 0
VeinTech, Unit 3/4 Gould Street, Osborne Park, Perth, Western Australia 6017
Country 152022 0
Australia
Phone 152022 0
+61 435 270 526
Fax 152022 0
Email 152022 0
Contact person for public queries
Name 152023 0
Michael D Liddelow
Address 152023 0
VeinTech, Unit 3/4 Gould Street, Osborne Park, Perth, Western Australia 6017
Country 152023 0
Australia
Phone 152023 0
+61 435 270 526
Fax 152023 0
Email 152023 0
Contact person for scientific queries
Name 152024 0
Michael D Liddelow
Address 152024 0
VeinTech, Unit 3/4 Gould Street, Osborne Park, Perth, Western Australia 6017
Country 152024 0
Australia
Phone 152024 0
+61 435 270 526
Fax 152024 0
Email 152024 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.